obesity

News

Novo Nordisk's CagriSema data disappoints investors again

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Lilly uses Oscars ad to warn about 'untested' GLP-1s

Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.

News

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

Novo Nordisk's CagriSema data disappoints investors again

Novo Nordisk follows Lilly into DTC obesity drug market

Lilly uses Oscars ad to warn about 'untested' GLP-1s

AbbVie pays Gubra $350m upfront to enter obesity field

Lilly launches discounted high-strength Zepbound vials in US

Compounders cast adrift after semaglutide shortage ends

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks